SCIENTIFIC REPORTS Clause Samples

SCIENTIFIC REPORTS. The Beneficiaries will submit through the Swiss Beneficiary short annual reports and a final report to the SNSF on the advancement of their project, providing information about timelines and progress made in implementing the JRP. The annual reports will be checked by the SNSF. The final report will be checked by the member of the evaluation panel that was responsible for the given proposal and will need to be approved by the Specialised Committee of the SNSF and the CSF Board. The report (approved) is the only document which serves as a basis for declaring the project completed. Financial reports: The beneficiaries will provide an annual and a final financial report to the SNSF and the CSF. The “Swiss PIs” in the JRP provide an annual and a final financial report to the SNSF, covering the expenses and revenues of the JRP financed by Switzerland (86.91%). This includes a financial report from the Croatian PIs, covering the expenses and revenues transferred by the Swiss PI (financed by Switzerland). Additionally, the Croatian PI compiles a second report to the CSF, accounting for the costs covered by the Croatian contribution (13.09%). The budget of the Croatian beneficiary will thus be clearly divided into a part funded by Switzerland and a part funded by Croatia. The Croatian contribution shall be calculated using the middle exchange rate of the Croatian National Bank (▇▇▇.▇▇▇.▇▇) prevailing on the date of conclusion of the Research Fund Agreement (10.07.2017) as a reference for the conversion from Swiss Francs to Croatian Kunas to calculate its 13.09%. For the reporting on the Croatian contribution (Croatian PI), a daily middle exchange rate of the Croatian National Bank prevailing at the last working day of the reporting period will act as reference for the conversion from Croatian Kuna to Swiss Franc. In the financial reports, expenditures will be compared with the initial budgets submitted. Financial reports will also be checked against the guidelines established at the start of the programme. Both the SNSF and the CSF will check and approve these reports (through Interdisciplinary and International Co-operation division and the CSF Board). Templates and necessary instructions for both types of report will be provided by the SNSF and the CSF.

SCIENTIFIC REPORTS. (a) NeoGenesis will keep and maintain adequate records containing laboratory data generated in the course of the Program to enable it to furnish complete and accurate information to OGS regarding the Program activities and results, including all Preliminary Compounds, Active Compounds and NeoMorph Focused Libraries identified in the Program and all Program Intellectual Property developed during the Program. All such written records of NeoGenesis shall be open to inspection by OGS during normal business hours upon reasonable prior written notice. (b) NeoGenesis shall provide OGS with reasonably-detailed written reports describing the results of the research performed pursuant to the Program including all Preliminary Compounds, Active Compounds and NeoMorph Focused Libraries identified in the Program. Such reports shall be delivered to OGS at least monthly during the Program. NeoGenesis will deliver a Final Target Report (as defined in ATTACHMENT A) with respect to the Program work performed on each Target including a description of all the Preliminary Compounds, Primary Active Compounds and NeoMorph Sublibraries identified during the Program with respect to such Target.

SCIENTIFIC REPORTS. (a) NeoGenesis will keep and maintain adequate records containing laboratory data generated in the course of the Program to enable it to furnish complete and accurate information to CUSTOMER regarding the Program activities and results, including but not limited to all Preliminary Compounds, Primary Active Compounds and NeoMorph Focused Libraries identified or used in the Program and all NeoGenesis Program Intellectual Property developed during the Program. All such written records of NeoGenesis shall be open to inspection by CUSTOMER during normal business hours upon reasonable prior written notice. (b) NeoGenesis shall provide CUSTOMER with reasonably-detailed written reports describing the results of the research performed pursuant to the Program including but not limited to all Preliminary Compounds, Primary Active Compounds, Selected Compounds and NeoMorph Focused Libraries identified or used in the Program. Such reports shall be delivered to CUSTOMER at least monthly during the Program. NeoGenesis will deliver a Primary Active Compounds Report with respect to the Program work performed on each Target. NeoGenesis will also deliver a Final Target Report on each Selected Compound after optimization and screening of the NeoMorph Focused Libraries.

SCIENTIFIC REPORTS. The Coordinator is responsible for the preparation of the annual scientific reports. The project contact persons are responsible for providing the Coordinator the reports.

SCIENTIFIC REPORTS. (a) NeoGenesis will keep and maintain adequate records containing laboratory data generated in the course of the Screening Program to enable it to furnish complete and accurate information to Tularik regarding the Screening Program activities and results, including all Preliminary Compounds, Primary Active Compounds and NeoMorph Focused Libraries identified in the Screening Program and all Program Intellectual Property described in clauses (a) or (b) of the Program Intellectual Property definition. All such written records of NeoGenesis shall be open to inspection by Tularik during normal business hours upon reasonable prior notice. (b) NeoGenesis shall provide Tularik with reasonably-detailed written reports describing the results of the research performed pursuant to the Screening Program including all Preliminary Compounds, Primary Active Compounds and NeoMorph Focused Libraries identified in the Screening Program and Program Intellectual Property described in clauses (a) or (b) of the Program Intellectual Property definition. Such reports shall be delivered to Tularik at least monthly during the Screening Program. Representatives of NeoGenesis will make themselves reasonably available to discuss such reports and the progress of the Screening Program. NeoGenesis will deliver a Final Target Report (as defined in ATTACHMENT A) with respect to the Screening Program work performed on each Target including a description of all the Preliminary Compounds, Primary Active Compounds and NeoMorph Focused Libraries identified during the Screening Program with respect to such Target.

SCIENTIFIC REPORTS. (a) NeoGenesis will keep and maintain adequate records containing laboratory data generated in the course of the Screening Program to enable it to furnish complete and accurate information to Immusol regarding the Screening Program activities and results, including all Program Intellectual Property described in clauses (a) or (b) of the Program Intellectual Property definition. All such written records of NeoGenesis shall be open to inspection by Immusol during normal business hours upon reasonable prior notice. (b) NeoGenesis shall provide Immusol with reasonably-detailed written reports describing the results of the research performed pursuant to the Screening Program including all Program Intellectual Property described in clauses (a) or (b) of the Program Intellectual Property definition. Such reports shall be delivered to Immusol at least quarterly during the Screening Program. Representatives of NeoGenesis will make themselves reasonably available to discuss such reports and the progress of the Screening Program. NeoGenesis will deliver a Final Target Report (as defined in ATTACHMENT A) with respect to the Screening Program work performed on each Shared Target.

SCIENTIFIC REPORTS. 2014, 4 (1), 1–10. DOI: 10.1038/srep05797.

SCIENTIFIC REPORTS. Reports to be provided: (a) Semi-annual scientific reports as of March 31st and September 30th of each year during the Term within (30) days; (b) a final scientific report within thirty (30) days after the Completion Date or upon termination of this Agreement;

SCIENTIFIC REPORTS. The Beneficiaries will submit through the Swiss Beneficiary short annual reports and a final report to SNSF on the advancement of their project, providing information about timelines and progress made in implementing the JRP. The annual reports will be checked by SNSF. The final report will be checked by the member of the evaluation panel that was responsible for the given proposal and will need to be approved by SNSF and the UEFISCDI. The report (approved) is the only document which serves as a basis for declaring the project completed.